Get the Stockscreener App
10.86
0.91%
-0.10
Eikon Therapeutics Inc stock is traded at $10.86, with a volume of 238.69K.
It is down -0.91% in the last 24 hours and up +13.60% over the past month.
Eikon Therapeutics Inc is a late-stage clinical biopharmaceutical company dedicated to building a world-wide , fully-integrated organization developing important, medicines to address serious unmet medical needs. It operates in a single operating segment, which is in the business of drug discovery leveraging its proprietary technology and clinical development of its product candidates. Its product candidates include: EIK1001, EIK1003, EIK1004, EIK1005, and EIK1006.
See More
Previous Close:
$10.96
Open:
$10.81
24h Volume:
238.69K
Relative Volume:
0.60
Market Cap:
$588.23M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-2.4236
EPS:
-4.481
Net Cash Flow:
-
1W Performance:
-1.09%
1M Performance:
+13.60%
6M Performance:
-28.36%
1Y Performance:
+0.00%
1-Day Range:
$10.62
$11.05
1-Week Range:
$10.10
$11.67
52-Week Range:
$7.90
$16.50
Eikon Therapeutics Inc Stock (EIKN) Company Profile
Name
Eikon Therapeutics Inc
Sector
Industry
Phone
341-777-0566
Address
230 HARRIET TUBMAN WAY, MILLBRAE
Compare EIKN vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EIKN
Eikon Therapeutics Inc
|
10.86 | 582.27M | 0 | 0 | 0 | -4.481 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Eikon Therapeutics Inc Stock (EIKN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-02-26 | Initiated | BofA Securities | Buy |
| Mar-02-26 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-02-26 | Initiated | JP Morgan | Overweight |
| Mar-02-26 | Initiated | Mizuho | Outperform |
| Mar-02-26 | Initiated | Morgan Stanley | Overweight |
| Feb-26-26 | Initiated | Wedbush | Underperform |
View All
Eikon Therapeutics Inc Stock (EIKN) Latest News
Cantor Fitzgerald reiterates Overweight on Eikon stock - Investing.com
Eikon Therapeutics adds Merck chemistry head to advisory board By Investing.com - Investing.com Nigeria
Eikon Therapeutics to Participate in KOL Event on Therapeutic Use of PARP Inhibitors in Oncology Hosted by Cantor Fitzgerald - Sahm
An oncology expert will discuss PARP drugs in four cancers Aug. 20 - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
EIKN Q1 2026 Earnings: Deeper-than-Expected Loss but Shares Rally 6.97%Energy Earnings Report - vinanet.vn
$Eikon Therapeutics (EIKN.US)$ - Moomoo
Form 8K EIKON THERAPEUTICS For: 14 August By Investing.com - Investing.com Australia
Eikon Therapeutics Updates Corporate Presentation, Files Form 8-K Under Regulation FD - kalkinemedia.com
Eikon Therapeutics, Inc. Stock 12‑Month Price Target Cut to $24.6, Implies 138% Upside - TradingView
Possible Turnaround For Eikon Therapeutics Insiders, Still Down US$852k - simplywall.st
Eikon Therapeutics, Inc. Announces Appointment of Ma. Fatima D. Francisco as Independent Director and to the Compensation Committee - marketscreener.com
Eikon Therapeutics, Inc. 2Q 2026: Net income $(88.4)M, EPS $(1.63) — 10-Q Summary - TradingView
Eikon Therapeutics (EIKN) reports $171.4M first-half loss and $531M cash - Stock Titan
Eikon Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Eikon Therapeutics Reports Second Quarter 2026 Financial Results and Provides Clinical Updates - Yahoo Finance
FMR LLC Expands Eikon Therapeutics Inc (EIKN) Stake Despite Post-IPO Slide - GuruFocus
Eikon Therapeutics Announces Dose Selection for TeLuRide-006, an Ongoing Adaptive Phase 2/3 Trial of EIK1001 in Advanced Melanoma - The Manila Times
Eikon Therapeutics Selects Dose For TeLuRide-006 Adaptive Phase 2/3 Trial Of EIK1001 In Advanced Melanoma - marketscreener.com
Eikon Therapeutics Selects Dose in Phase 2/3 Trial of Investigational Melanoma Treatment - marketscreener.com
Eikon Therapeutics Appoints Johnny Bennett, Ph.D. To Its Scientific Advisory Board - TradingView
Eikon Therapeutics adds Merck chemistry head to advisory board - Investing.com
Eikon Therapeutics Appoints Johnny Bennett, Ph.D. to its Scientific Advisory Board - The Manila Times
Press Release: Eikon Therapeutics Appoints Johnny Bennett, Ph.D. to Its Scientific Advisory Board - Moomoo
Eikon Therapeutics, Inc. Announces Appointment of Johnny Bennett, Ph.D. to Scientific Advisory Board - marketscreener.com
GYRE Stock Price and Chart — NASDAQ:GYRE - TradingView
FMR LLC reports 9.2% Eikon Therapeutics (EIKN) ownership on amended 13G - Stock Titan
Certain Warrants of Eikon Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 4-AUG-2026. - marketscreener.com
Two Eikon Therapeutics, Inc. (Nasdaq: EIKN) directors step down - Stock Titan
Eikon Therapeutics, Inc.'s (NASDAQ:EIKN) Lock-Up Period Will Expire on August 4th - MarketBeat
Eikon Therapeutics Shares Up on First Dose to Patient in Phase 2/3 Lung Cancer Trial - Moomoo
Baker Hughes Posts Upbeat Q2 Earnings, Joins Forte Biosciences, Eikon Therapeutics And Other Big Stocks M - Benzinga
Eikon Therapeutics doses first patient in lung cancer trial - Investing.com
Eikon Therapeutics Doses First Patient in Phase 2/3 Trial for EIK1001 in Non-Small Cell Lung Cancer - marketscreener.com
Eikon Therapeutics doses first patient in lung cancer trial By Investing.com - Investing.com Canada
Eikon Therapeutics Doses First Patient in Phase 2/3 TeLuRide-008 Trial of EIK1001 for First-Line Stage 4 NSCLC - Quiver Quantitative
Eikon Therapeutics Announces First Patient Dosed in TeLuRide-008, a Registrational Phase 2/3 Trial of EIK1001 in Non-Small Cell Lung Cancer - GlobeNewswire
Eikon Therapeutics Ord Shs (EIKN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Eikon Therapeutics Ord Shs (EIKN) Institutional Confidence - TradingKey
Eikon Therapeutics, Inc. Revenue Breakdown – BX:EIKN - TradingView
Eikon Therapeutics: Behind The Rough Debut (NASDAQ:EIKN) - Seeking Alpha
Eikon Therapeutics Announces Seven Abstracts Accepted for Presentation at the 2026 European Society of Medical Oncology (ESMO) Congress - The Manila Times
Eikon Therapeutics Announces Seven Abstracts Accepted for Presentation at the 2026 European ... - Caledonian Record
Seven Eikon abstracts include lung and prostate cancer studies at ESMO - Stock Titan
Eikon Therapeutics (EIKN) Short Interest & Short Float | Updated Jul 2026 - MarketBeat
Is Eikon Therapeutics, Inc. (EIKN) Stock a Biotech Growth Opportunity Despite Limited Q1 Updates? - Yahoo Finance
Eikon Therapeutics (EIKN) Surges Over 11% as Bullish Momentum BuildsAccumulation Line - dars.gov.et
Eikon Therapeutics, Inc.(NasdaqGS: EIKN) added to Russell 2000 Index - marketscreener.com
Eikon Therapeutics, Inc.(NasdaqGS:EIKN) added to Russell Microcap Value Benchmark Index - marketscreener.com
Eikon Therapeutics, Inc.(NasdaqGS: EIKN) added to Russell 2000 Value Benchmark - marketscreener.com
Eikon Therapeutics, Inc.(NasdaqGS:EIKN) added to Russell Microcap Growth Benchmark Index - marketscreener.com
Eikon Therapeutics Inc Stock (EIKN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Eikon Therapeutics Inc Stock (EIKN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Foresite Capital Management IV | 10% Owner |
Feb 04 '26 |
Buy |
18.00 |
55,555 |
999,990 |
1,318,983 |
| FRAZIER KENNETH C | Director |
Feb 04 '26 |
Buy |
18.00 |
111,111 |
1,999,998 |
111,111 |
| Wolfe Josh | Director |
Feb 04 '26 |
Buy |
18.00 |
277,776 |
4,999,968 |
138,888 |
| Lux Venture Partners V, LLC | 10% Owner |
Feb 04 '26 |
Buy |
18.00 |
277,776 |
4,999,968 |
138,888 |
0.86%
0.31%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):